Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is 2.14 as of 2026-10-06T18:04:26.148Z.
Calculation as of: 2026-10-06T18:04:26.148Z.
Quote observation: 2026-10-06T18:00:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
2.14
SECTOR MEDIAN · HEALTHCARE
2.39
median of 751 covered companies
CURRENT VS SECTOR MEDIAN
-10.46%
vs the sector median at left
Market Cap
$946.27M
PB Ratio
2.24
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$868.65M
PB Ratio
3.86
TTM Avg
10.91
3Y Avg
9.69
5Y Avg
6.24
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $901.55M | 2.14 | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $913.78M | 2.56 | 2.08 | 2.35 | 2.28 |
| Bioventus Inc. (BVS)vs › | $899.02M | 3.94 | 3.59 | 3.23 | 2.55 |
| MoonLake Immunotherapeutics (MLTX)vs › | $925.27M | 2.16 | 3.57 | 5.41 | 7.83 |
| CeriBell, Inc. (CBLL)vs › | $932.06M | 7.26 | 4.82 | 4.14 | 4.14 |
| Kura Oncology, Inc. (KURA)vs › | $938.44M | 19.38 | 7.49 | 4.20 | 3.31 |
| Arbutus Biopharma Corp (ABUS)vs › | $877.52M | 3.39 | 7.96 | 6.43 | 5.06 |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $946.27M | 2.24 | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | 3.86 | 10.91 | 9.69 | 6.24 |
| Savara Inc. (SVRA)vs › | $948.81M | 6.60 | 9.42 | 6.64 | 4.98 |
P/B Ratio
2.14
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
